Highlights
Recent News
Replimune’s Lead Drug Hits Second FDA Wall, Triggering Survival Mode
The U.S. Food and Drug Administration has delivered a potentially fatal blow to Replimune Group Inc., issuing a second complete...
Red Cat’s Defense Tech Ecosystem Nears Critical Junctions
Red Cat Holdings is accelerating the development of its autonomous systems ecosystem on multiple fronts, with a series of strategic...
Eutelsat’s Launchpad: Balancing Explosive LEO Growth with Rocket Reliance
Eutelsat shares surged more than 7% this week, capturing investor attention as the global space industry gathered for the 41st...
Hims & Hers: A Strategic Overhaul Tested by Margins and Market Sentiment
The stock of telehealth provider Hims & Hers has been under significant pressure, trading roughly 40 percent below its level...
Popular
Net Worth
ImmunityBio’s Record Revenue Meets Mounting Legal Pressure
ImmunityBio's stock is navigating a volatile path, caught between explosive commercial growth for its bladder cancer drug...
Strategy’s Solitary Bitcoin Bet: A $14.5 Billion Paper Loss and Unwavering Conviction
As corporate interest in Bitcoin evaporates, one company stands defiantly alone. Software firm Strategy continues to aggressively...
BioNTech’s Oncology Drive Gains Momentum with Key Data and Analyst Backing
Positive clinical results for a late-stage cancer drug candidate have strengthened BioNTech's strategic pivot away from its...
Shadow Banks, Record Defaults, and the $1.8 Trillion Fracture
Dear readers, On Thursday we wrote that next week's bank earnings would be the sorting mechanism—that loan-loss...